Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515575 · ClinicalTrials.gov registry record · Phase 2
A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
A Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 7
- Study locations
NCT05515575 is a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 8 participants, below the 86-participant average among 7 other Sarcoma,Soft Tissue trials with a reported enrollment target (91% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05515575, a Phase 2 study of Sarcoma,Soft Tissue and Sarcoma Uterus, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are groups of DDR mutations in soft tissue sarcoma cells that respond better to treatment with niraparib.
Conditions Studied
Interventions
- DRUG Niraparib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-23 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05515575
The ClinicalTrials.gov registry entry for NCT05515575 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 7 other Sarcoma,Soft Tissue trials with a reported enrollment target (91% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sarcoma,Soft Tissue appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.
NCT05515575 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05515575 about?
NCT05515575 is a clinical study titled "A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA". The purpose of this study is to test whether the study drug, niraparib, is effective against unresectable and/or metastatic soft tissue sarcoma with DDR mutations. The researchers will also study whether niraparib is safe and causes few or mild side effects, and whether there are groups of DDR mutat...
What is the current status of trial NCT05515575?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-08-23. Estimated completion is 2026-08.
What conditions does trial NCT05515575 study?
This clinical trial studies the following conditions: Sarcoma,Soft Tissue, Sarcoma Uterus.
What interventions are being tested in trial NCT05515575?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT05515575?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05515575 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma,Soft Tissue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
ACTIVE NOT RECRUITING · Phase 2
-
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
RECRUITING · Phase 1
-
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.